Keytruda is a medication that is used to treat melanoma, a type of skin cancer. Keytruda, also known as pembrolizumab, is an immune checkpoint inhibitor that works by blocking a protein called PD-1 on T cells, which helps the immune system recognize and attack cancer cells.

Like all medications, Keytruda has potential side effects that patients should be aware of. The most common side effects of Keytruda include fatigue, rash, itching, diarrhea, nausea, decreased appetite, constipation, joint pain, and fever [2]. However, these side effects are generally mild and can be managed with medication or other supportive care.

More serious side effects of Keytruda are less common but can be severe. These include lung problems, liver problems, kidney problems, intestinal problems, hormone gland problems, skin problems, and other immune system problems [2]. These side effects can be life-threatening and require immediate medical attention.

According to a recent study published by the National Cancer Institute, patients who receive immune checkpoint inhibitors like Keytruda for melanoma may experience long-term side effects, including autoimmune disorders and endocrine dysfunction [3]. These side effects can occur months or even years after treatment has ended and can significantly impact a patient's quality of life.

It is important for patients to discuss the potential side effects of Keytruda with their healthcare provider before starting treatment. Patients should also report any new or worsening symptoms to their healthcare provider immediately.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/side-effects/
[3] https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects